{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:16:29Z","timestamp":1783988189086,"version":"3.55.0"},"reference-count":55,"publisher":"BMJ","issue":"5","funder":[{"name":"Astra Zeneca"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>The antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease (APPLE COPD-ICON2) trial is a prospective 2\u00d72\u2009factorial, double-blinded proof-of-concept randomised controlled trial targeting patients with chronic obstructive pulmonary disease (COPD) at high risk of cardiovascular disease. The primary goal of this trial is to investigate if treatment with antiplatelet therapy will produce the required response in platelet function measured using the Multiplate test in patients with COPD.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>Patients with COPD are screened for eligibility using inclusion and exclusion criteria. Eligible patients are randomised and allocated into one of four groups to receive aspirin plus placebo, ticagrelor plus placebo, aspirin plus ticagrelor or placebo only. Markers of systemic inflammation, platelet reactivity, arterial stiffness, carotid intima-media thickness (CIMT), lung function and quality of life questionnaires are assessed. The primary outcome consists of inhibition (binary response) of aspirin and ADP-induced platelet function at 6\u2009months. Secondary outcomes include changes in inflammatory markers, CIMT, non-invasive measures of vascular stiffness, quality of life using questionnaires (EuroQol\u2013five dimensions\u2013five levels of perceived problems (EQ5D-5L), St. George\u2019s COPD questionnaire) and to record occurrence of repeat hospitalisation, angina, myocardial infarction or death from baseline to 6\u2009months. Safety outcomes will be rates of major and minor bleeding, forced expiratory volume in 1 s, forced vital capacity and Medical Research Council dyspnoea scale.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study was approved by the North East-Tyne and Wear South Research Ethics Committee (15\/NE\/0155). Findings of the study will be presented in scientific sessions and published in peer-reviewed journals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration number<\/jats:title>\n<jats:p>\n<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT43245574\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\">NCT43245574<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2017-020713","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:48:27Z","timestamp":1684172907000},"page":"e020713","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: protocol of a randomised controlled proof-of-concept trial (APPLE COPD-ICON 2)"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct43245574","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"given":"Vijay","family":"Kunadian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"McColl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"von Wilamowitz-Moellendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Stocken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"De Soyza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,5,26]]},"reference":[{"key":"2023050822104822000_8.5.e020713.1","unstructured":"Healthcare Commission. Clearing the air. A national study of chronic obstructive pulmonary disease. London: Healthcare Commission, 2006."},{"key":"2023050822104822000_8.5.e020713.2","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e318279e907"},{"key":"2023050822104822000_8.5.e020713.3","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10122794"},{"key":"2023050822104822000_8.5.e020713.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2005.04.008"},{"key":"2023050822104822000_8.5.e020713.5","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00012408"},{"key":"2023050822104822000_8.5.e020713.6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1081\/COPD-200050671","article-title":"Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999","volume":"2","author":"Mapel","year":"2005","journal-title":"COPD"},{"key":"2023050822104822000_8.5.e020713.7","first-page":"343","article-title":"[Mortality and comorbidity in hospitalized chronic obstructive pulmonary disease patients]","volume":"79","author":"Rubinsztajn","year":"2011","journal-title":"Pneumonol Alergol Pol"},{"key":"2023050822104822000_8.5.e020713.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr338"},{"key":"2023050822104822000_8.5.e020713.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2110093"},{"key":"2023050822104822000_8.5.e020713.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-011-9301-8"},{"key":"2023050822104822000_8.5.e020713.11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.amepre.2014.03.014","article-title":"Burden of cardiovascular disease in chronic obstructive pulmonary disease","volume":"47","author":"Agarwal","year":"2014","journal-title":"Am J Prev Med"},{"key":"2023050822104822000_8.5.e020713.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-203151"},{"key":"2023050822104822000_8.5.e020713.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071014"},{"key":"2023050822104822000_8.5.e020713.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.157529"},{"key":"2023050822104822000_8.5.e020713.15","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2023050822104822000_8.5.e020713.16","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00087312"},{"key":"2023050822104822000_8.5.e020713.17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310897"},{"key":"2023050822104822000_8.5.e020713.18","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2306"},{"key":"2023050822104822000_8.5.e020713.19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707364"},{"key":"2023050822104822000_8.5.e020713.20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/bph.13429","article-title":"Effects of P2Y12 receptor antagonists beyond platelet inhibition\u2013comparison of ticagrelor with thienopyridines","volume":"173","author":"Nylander","year":"2016","journal-title":"Br J Pharmacol"},{"key":"2023050822104822000_8.5.e020713.21","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.842965"},{"key":"2023050822104822000_8.5.e020713.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2015.02.006"},{"key":"2023050822104822000_8.5.e020713.23","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.781502"},{"key":"2023050822104822000_8.5.e020713.24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002490"},{"key":"2023050822104822000_8.5.e020713.25","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203996"},{"key":"2023050822104822000_8.5.e020713.26","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309871"},{"key":"2023050822104822000_8.5.e020713.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr204"},{"key":"2023050822104822000_8.5.e020713.28","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.76.1.142"},{"key":"2023050822104822000_8.5.e020713.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449"},{"key":"2023050822104822000_8.5.e020713.30","first-page":"113","article-title":"High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction","volume":"17","author":"Jakl","year":"2017","journal-title":"Anatol J Cardiol"},{"key":"2023050822104822000_8.5.e020713.31","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203608"},{"key":"2023050822104822000_8.5.e020713.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.08.005"},{"key":"2023050822104822000_8.5.e020713.33","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2113"},{"key":"2023050822104822000_8.5.e020713.34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/TH07-07-0478","article-title":"Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment","volume":"99","author":"Sibbing","year":"2008","journal-title":"Thromb Haemost"},{"key":"2023050822104822000_8.5.e020713.35","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.039","article-title":"Effect of plasma fibrinogen, high-sensitive C-reactive protein, and cigarette smoking on carotid atherosclerosis: the suita study","volume":"24","author":"Kawase Ishihara","year":"2015","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2023050822104822000_8.5.e020713.36","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000056767.69054.B3"},{"key":"2023050822104822000_8.5.e020713.37","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.5.3618"},{"key":"2023050822104822000_8.5.e020713.38","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200701-004FM"},{"key":"2023050822104822000_8.5.e020713.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-008-9106-6"},{"key":"2023050822104822000_8.5.e020713.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2015.01.019"},{"key":"2023050822104822000_8.5.e020713.41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/COPD.S1401","article-title":"Mechanisms of atherothrombosis in chronic obstructive pulmonary disease","volume":"3","author":"Fimognari","year":"2008","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2023050822104822000_8.5.e020713.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.040"},{"key":"2023050822104822000_8.5.e020713.43","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.083493"},{"key":"2023050822104822000_8.5.e020713.44","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200707-1080OC"},{"issue":"Suppl 3","key":"2023050822104822000_8.5.e020713.45","first-page":"A12457","article-title":"Abstract 12457: carotid intima-media thickness and aortic stiffness are elevated in Chronic Obstructive Pulmonary Disease (COPD) subjects compared to controls and not associated with systemic inflammation","volume":"132","author":"Fisk","year":"2015","journal-title":"Circulation"},{"key":"2023050822104822000_8.5.e020713.46","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00169313"},{"key":"2023050822104822000_8.5.e020713.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.artres.2009.02.002"},{"key":"2023050822104822000_8.5.e020713.48","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000092"},{"key":"2023050822104822000_8.5.e020713.49","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-012-0272-9"},{"key":"2023050822104822000_8.5.e020713.50","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.10.0680"},{"key":"2023050822104822000_8.5.e020713.51","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejcdt.2012.08.012","article-title":"Quality of life in COPD patients","volume":"61","author":"Zamzam","year":"2012","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2023050822104822000_8.5.e020713.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.004"},{"key":"2023050822104822000_8.5.e020713.53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11136-013-0498-2","article-title":"The quality of life questionnaire EQ-5D-5L: psychometric properties and normative values for the general German population","volume":"23","author":"Hinz","year":"2014","journal-title":"Qual Life Res"},{"key":"2023050822104822000_8.5.e020713.54","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2961"},{"key":"2023050822104822000_8.5.e020713.55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-014-1119-9","article-title":"Comparison of platelet inhibition by prasugrel versus ticagrelor over time in patients with acute myocardial infarction","volume":"39","author":"Perl","year":"2015","journal-title":"J Thromb Thrombolysis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-020713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T17:48:48Z","timestamp":1684172928000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-020713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,26]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1136\/bmjopen-2017-020713"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-020713","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}